P Czodrowski, ABSTRACT: The mediator complex-associated cyclin dependent kinase CDK8 regulates β-catenin-dependent transcription following activation of WNT signaling. Multiple lines of evidence suggest CDK8 may act as an oncogene in the development of colorectal cancer. Here we describe the successful optimization of an imidazo-thiadiazole series of CDK8 inhibitors that was identified in a high-throughput screening campaign and further progressed by structure-based design. In several optimization cycles, we improved the microsomal stability, potency, and kinase selectivity. The initial imidazo-thiadiazole scaffold was replaced by a 3-methyl-1H-pyrazolo[3,4-b]-pyridine which resulted in compound 25 (MSC2530818) that displayed excellent kinase selectivity, biochemical and cellular potency, microsomal stability, and is orally bioavailable. Furthermore, we demonstrated modulation of phospho-STAT1, a pharmacodynamic biomarker of CDK8 activity, and tumor growth inhibition in an APC mutant SW620 human colorectal carcinoma xenograft model after oral administration. Compound 25 demonstrated suitable potency and selectivity to progress into preclinical in vivo efficacy and safety studies.
■ INTRODUCTION
In contrast to other members of the CDK family (e.g., CDK1, CDK2, and CDK4/6), neither CDK8 nor its paralogue CDK19 are required for the regulation of cell cycle progression. Instead, CDK8 and CDK19 together with MED12/12L and MED13/ 13L respectively form a regulatory kinase module for the mediator complex. 1, 2 The mediator complex is a large protein assembly that couples gene-specific transcriptional regulators to the general RNA polymerase II transcription machinery. 2−7 CDK8 and CDK19 participate in the regulation of transcription through phosphorylation of RNA polymerase II 8 and other transcription factors to regulate their activity or tag them for proteosomal degradation. 9−14 The role of CDK19 in cellular biology and human disease is not well understood and is the subject of ongoing investigation. 1 However, in contrast, CDK8 is much better characterized and has been proposed to act as an oncogene in colon cancer 15 and approximately 60% of colorectal cancers have increased CDK8 gene copy number. 16 Moreover, a worse prognosis in colon, breast, and ovarian cancer is linked to increased CDK8 expression. 17 CDK8 is also essential for cell proliferation in melanoma. 18 Additional cancer-relevant activities of CDK8 include growth factor-induced transcription, modulation of TGF β-signaling, 13 and phosphorylation of the Notch intracellular domain. 19, 20 Although knockout of CDK8 prevents embryonic development due to its essential role in the pluripotent stem cell, other studies have reported that CDK8 depletion does not affect the growth of normal cells. 15, 21, 22 CDK8 may also contribute to tumorigenesis through activation of β-catenin regulated gene expression, 16 a core transcriptional regulator of canonical WNT signaling. Consistent with this observation, expression of the CDK8 gene is correlated with activation of β-catenin in colon and gastric cancers. 17, 23 Because of its involvement as a regulator of WNT/ β-catenin signaling, CDK8 may be linked with disorders and diseases in which activation of WNT/β-catenin is crucial such as hyperproliferative, inflammatory, or degenerative disorders and several malignant diseases. 19, 20 An extensive contemporary review reports the current status of small-molecule inhibitors for CDK8/CDK19 and highlights an increasing interest in targeting CDK8; 24 in addition, a recent report demonstrates a potential use for CDK8 inhibitors in AML. 25 We recently described the discovery of small-molecule inhibitors of CDK8 from a cell-based high-throughput screen (HTS) seeking WNT signaling inhibitors and also reported additional differentiated series of CDK8 inhibitors from a scaffold-hopping approach using the biochemical screen reported herein. 26−30 Here we describe the identification of a novel CDK8/19 chemotype from a biochemical HTS versus CDK8 and its subsequent optimization, enabled by structurebased design, to give compound 25, a potent, selective, and orally bioavailable CDK8/19 ligand suitable for further progression into preclinical studies.
■ RESULTS AND DISCUSSION
In a CDK8 high-throughput screen using a FRET-based Lanthascreen binding competition assay, 27 we identified several hit compounds with submicromolar activity. Our hit series contained an imidazo [5,1-b] [1, 3, 4] thiadiazole scaffold, henceforth described as the "imidazo-thiadiazole" series. Initial hits bore either a 2-substituted benzyl substituent (1 and 2) or a 2-phenylpyrrolidine ring (3 and 4) attached to the imidazothiadiazole scaffold via an amide bond at the 2-position ( Table  1) . As a cellular readout of WNT signaling, we used our previously described 7dF3 WNT-specific reporter gene assay 31 and observed a 3−13-fold drop off from in vitro CDK8 binding affinity to cell-based activity for compounds 1−4.
Introduction of a methyl group to the alkyl linker resulted in a 6-fold drop in biochemical potency (compound 2, Table 1) , and the pyrrolidine moiety was favored over an alkyl chain linker by virtue of significantly increased cell-based potency and improved metabolic stability (compounds 3 and 4). Hydrogen to fluorine exchange at the para position of the phenyl ring (compounds 3 to 4) did not influence biochemical or cell-based potency; however, we noted a slight improvement in microsomal stability (Table 1) . To further explore the impact of the para-substitution and stereochemistry at the pyrrolidine 2-position, the racemic form and both of the enantiomers bearing a p-Cl-phenyl were synthesized ( Table 2 ). The racemic form (5) showed modest biochemical and cell-based activity. Interestingly, the S-enantiomer (6) was significantly more active than the R-enantiomer (7); however, the microsomal stability of both enantiomers was in the same range.
To understand the binding mode and to inform further medicinal chemistry design, we determined the crystal structure of the most potent enantiomer (6) bound to CDK8/cyclin C ( Figure 1A ). Compound 6 is bound to the hinge region of CDK8 (Ala100) via the nitrogen atom at the 6-position of the "imidazo-thiadiazole" scaffold, while the 5-methyl group points away from the gatekeeper residue (Phe97) toward the solventexposed channel. The carbonyl group of the C2-amide forms a cation−π interaction to the catalytic lysine residue (Lys52), too distant (3.6 Å) to be considered as a hydrogen bond. The sulfur atom of the "imidazo-thiadiazole" scaffold is positioned to form favorable van der Waals (vdW) interactions to the gatekeeper residue Phe97. The pyrrolidine ring also forms favorable vdW interactions to Tyr32 and the side chain of Asp173. Furthermore, the orientation of the pyrrolidine defines the exit vector for the p-Cl-phenyl substituent which itself forms vdW interactions with Val27, Tyr32, Val35, Leu158, and Arg356. We did not observe sufficient evidence to support a halogen bond between the chlorine atom and the backbone CO of Val27: the distance is 2.9 Å, and the angle between the chlorine atom and the CO functionality of Val27 is 104.7°.
Comparison of the structure of 6 in CDK8/cyclin C with our recently published crystal structure of a 3,4,5-trisubstituted-2-aminopyridine chemotype 27 (compound 8, CCT251921) revealed few structural differences in the active site. The CDK8 residues in the ATP binding site with the largest variance between the two crystal structures are shown ( Figure  1B ). Despite the different modes of ligand-binding, the protein structure is largely conserved. Compounds 6 and 8 27 both form H-bond acceptor interactions with the backbone NH of hinge residue Ala100 and interact with the catalytic lysine (Lys52) through the amide and lactam carbonyl groups, respectively. However, interaction with the gatekeeper residue Phe97 is mediated by the sulfur atom of the thiadiazole scaffold 6 as opposed to the 3-chloro substituent in compound 8. Most notably, the para-chlorophenyl and N-methylindazole rings that project into a similar region in the CDK8 solvent channel are linked to the hinge-binding scaffold through different architectures in the two series ( Figure 1B ).
We were concerned that the thiadiazole ring may be prone to oxidative metabolism and therefore set out to discover a modified scaffold hop in order to mitigate this risk. In addition, we wished to explore variation of the pyrrolidine ring and its 
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1. Scaffold Hop from the Hinge Binding Motif of the "Imidazo-thiadiazole" Series. We modified the "imidazothiadiazole" scaffold based upon the crystal structure of compound 6 in CDK8/cyclin C ( Figure 1A ) according to SZMAP 32 and WaterMap 33 analysis (see Figure 2 ). We ran these calculations for the ligand-deleted form of the crystal structure of compound 6 with CDK8/cyclin C. Given this calculation setup, we could analyze the energy of predicted water sites inside the hinge binding region and identify possible handles for scaffold variations.
Solvent ZAP Mapping (SZMAP; ZAP is a Poisson− Boltzmann solver) represents a mixture of an implicit and explicit solvent model. In brief, a grid with a spacing of 0.25 Å is generated inside the protein active site and an explicit water molecule is positioned at each grid point with multiple orientations, followed by an implicit solvent Poisson− Boltzmann calculation. 34, 35 These calculations can be done with and without the ligand. For our analysis, we performed the calculations without the ligand. Once the calculations are completed for all grid points, an overall energy grid for the presence or absence of water molecules is computed. The predicted water molecules show different characteristics based on their energy values: a water molecule is characterized as "hydrophobic" if its energy value is positive, otherwise it is characterized as "hydrophilic".
The WaterMap methodology is a combination of MD simulation 36 with the inhomogeneous fluid approach. 37 In brief, this approach calculates the enthalpic and entropic contributions of binding per predicted water molecule. Consistent with the SZMAP analysis, the ligand was left out for the WaterMap calculations. If the overall free energy per predicted water molecule is positive, it is specified as "unhappy water", whereas a predicted negative free energy indicates a "happy water".
The interpretation of SZMAP and WaterMap calculations can be used for the differentiation of binding modes observed for highly structurally related ligands 38 and for rationalization of SAR, 33, 39 kinase selectivity, 40 and binding kinetics. 41 In the course of our studies, we employed SZMAP and WaterMap for the interpretation of modifications to the hinge binding scaffold. By applying these computational approaches, we explored changes to the five-membered ring of the hinge binding motif and selected a range of 5,6-bicyclic scaffolds for synthesis. The remainder of the molecule was fixed by the S-pCl-2-phenyl-pyrrolidine motif (Table 3 ) and compounds were scored by WaterMap, see Figure 2C .
Analysis of the predicted water sites via SZMAP (see Figure  2B ) revealed that hydrophilic water molecules are favored directly adjacent to the hinge residues Ala100 and Asp98. This is consistent with the corresponding hydrophilic hinge-binding motifs of our selected scaffold replacements. The remaining part of the hinge-binding region is predicted to be mostly filled with hydrophobic water molecules. Such water molecules can be replaced by both hydrophobic and hydrophilic moieties. 42−44 On the basis of this finding, we ranked our compound ideas by WaterMap scores. In addition, the characterization of predicted water sites by SZMAP calculations revealed that broad scaffold variations should be possible. The new compound design ideas were also prioritized based upon their synthetic tractability and potential for improved microsomal stability. Figure 2B (lower panel) depicts the contribution from each ligand atom resulting from water molecule replacement at the same position. This analysis underscores the 30-fold difference in CDK8 affinity between compounds 9 and 10: the favorable binding contribution by addition of a methyl group at the 5-position is driven by the replacement of an "unhappy" water molecule; this finding is consistent with both the WaterMap and SZMAP predictions. We performed a ranking of our compounds based on the WaterMap scores for the docking solutions of compounds from Tables 1 and 2 which adopt a similar hinge-binding mode. On the basis of an acceptable trend between WaterMap scores and pIC 50 , we also scored new compound ideas from Table 3 . The outcome of this ranking is given in Figure 2C (lower panel), suggesting a weak correlation between the WaterMap-based analysis and the in vitro potency of compounds from Table 3 . We omitted compound 11 from this analysis because we anticipate a different binding mode; indeed, a 2850-fold decrease in potency was seen with the introduction of an sp . WaterMap analysis of the CDK8/compound 6 crystal structure: red spheres correspond to "unhappy" water molecules and yellow spheres to "happy" water molecules. Lower panel: WaterMap scoring versus CDK8 pIC 50 for the compounds from Tables 1 and 2 (blue dots) and the compounds from Table 3 (red dots), r 2 = 0.54.
nitrogen atom juxtaposed to the CO backbone group of Asp98, see compound 11, versus the corresponding hydrogen bond donor in compound 10 (Table 3 ). However, compound 11 showed good microsomal stability, indicating that an appropriate scaffold hop could significantly improve stability to oxidative metabolism. Pleasingly, the introduction of a methyl group at the 3-position of the indazole 9 to give 10 resulted in a 22-fold improvement in biochemical potency and a 166-fold increase in cell-based potency; however, no improvement in microsomal stability was observed consistent with the increased lipophilicity of compound 10 versus 9. In summary, the potency increase arising from introduction of the C3-methyl group in compound 10 is consistent with our SZMAP analysis ( Figure 2B ). However, we recognized that the indazole C3-methyl group could be susceptible to oxidative metabolism and therefore introduced a more polar amino group at this position (compound 13), cognizant that improved hinge-binding interaction with the backbone carbonyl of Ala100 may also be realized (Figure 1 ). This tactic maintained in vitro CDK8 potency and improved microsomal stability as desired but unfortunately led to a 47-fold drop in cellular potency (compared to compound 10) despite good Caco2 flux (P appA-B = 33.7 × 10 −6 cm s
) and low efflux ratio (2.2). Compound 13 proved optimal in terms of biochemical potency and metabolic stability and was further profiled in a broad kinase panel to discover any kinase selectivity issues (Supporting Information, Table S2 ). Five off-target kinases were detected (JAK1, JAK2, JAK3, ROCK-II, and TYK2) and were subject to IC 50 determination to confirm potency (Table  4) . Consequently, we aimed to improve selectivity versus these off-target kinases in subsequent medicinal chemistry optimization.
2. Variation of the Ring Linker Size and Halogen Substituents. To inform our medicinal chemistry design, we calculated selectivity grids 45 for the CDK8/compound 6 crystal structure, see Figure 3A , and selectivity grids for the most notable off-target kinases, see Figure 3B . Selectivity grids represent a plausible interpretation of regions within binding pockets which may be targeted to improve (or to lose) selectivity. 45 These selectivity grids suggested that the parahalogen substituent of the phenyl ring and the 3-amino group of the indazole scaffold represented possible variation points to achieve selectivity for CDK8 over the off-target kinases, see Figure 3A . Furthermore, this analysis suggested that substitution at the solvent-exposed region of the binding pocket would nonspecifically increase potency against the off-target kinases, see Figure 3B . Therefore, we decided to vary the parahalogen substituent as well as the pyrrolidine ring and also to methylate the 3-amino group on the indazole scaffold in order to improve the selectivity and cell-based activity of compound 13 (Tables 3 and 5 ).
The kinase selectivity data confirmed the hypothesis that the para-substituent could act as selectivity handle: The % inhibition values, which refer to single point measurements of percent inhibition at 1 μM, demonstrate that the off-target activity versus the JAK family decreases as the para-halogen substituent is varied from Br to Cl to F. Selectivity could be further improved by modifications of the ring linker size or switching from a 1,2-substitution pattern to a 1,3-substitution pattern of the pyrrolidine linker. Pleasingly, the affinity for offtarget kinases was also reduced by methylating the 3-amino group.
In summary, variation of the halogen substituent in the paraposition of the phenyl ring showed a clear trend: while the ontarget biochemical CDK8 and cellular 7dF3 potencies decreased from Br to Cl to F in the matched trio 14, 13, and 15, less potent off-target activity versus the JAK family, ROCK-II and TYK2, was also observed. Interestingly, all three compounds were metabolically stable. Replacement of pyrrolidine (15) with azetidine (16) retained biochemical potency and microsomal stability with slight loss in cell-based potency. The same held true when increasing the ring size from a pyrrolidine to a piperidine linker (17) although cell-based potency was further eroded. Alteration of the substitution pattern at the pyrrolidine from 1,2 to 1,3 showed a moderate loss of biochemical and cellular potency (compare 18 with 13) while maintaining good microsomal stability. Finally, the addition of a methyl group to the 3-amino functionality of the indazole scaffold resulted in equipotent biochemical and cellular activity (compare 19 with 13) combined with a slight loss of microsomal stability.
We next determined the crystal structure of compound 17 bound to CDK8/cyclin C ( Figure 4A ) and examined the superposition of 17 with compound 6 ( Figure 4B ). The indazole hinge-binding motif is located at the same position as the "imidazo-thiadiazole" scaffold of 6. N1 of the indazole scaffold forms an additional hydrogen bond to the CO backbone of Asp98. The carbonyl moiety linking the para-halophenyl piperidine to the hinge-binding scaffold is located at the same position in both ligands. Interestingly, the exocyclic amino group in the 3-position of the indazole does not form a hydrogen bond with the backbone carbonyl atom of Ala100
(the heavy atom distance = 3.4 Å) and the electron density surrounding this amino group is not consistent with the placement of a water molecule. These observations are . Although the ring size is increased from a five-membered pyrrolidine linker to a six-membered piperidine linker, the p-F phenyl ring is placed at an almost identical position compared to compound 6, see Figure 4B . Comparing the fluorine atom (compound 17) to the chlorine atom (compound 6), the halogen to Val27 carbonyl distance is increased from 2.9 Å (compound 6, chlorine) to 3.7 Å (compound 17, fluorine). We observed only one other structural difference: the distance between the carbonyl linker and the catalytic lysine Lys52 (3.6 Å for compound 6 and 4.6 Å for compound 17). Thus, we attribute the increased potency of compound 6 to the improved interaction of the para-Cl atom with Val27 compared to the para-F atom in compound 17 together with improved interaction between the carbonyl linker and Lys52 for compound 6. Although we had improved the kinase selectivity and maintained microsomal stability by variations of the pyrrolidine linker and para-halogen substituent, the resultant compounds (16 and 17) lacked the desired biochemical potency and cellular activity. Comparison of the matched molecular pair C3-amino with C3-methyl (13 vs 10) indicated that the C3-methyl substitution resulted in good cellular potency, albeit with poorer microsomal stability. Consequently, we selected the C3-methylindazole scaffold for further progression.
3. Optimization of Microsomal Stability. In vitro metabolite identification studies indicated that the pyrrolidine ring linker is the major site of oxidative metabolism for compound 10. Thus, we prepared close analogues of compound 10 with reduced overall lipophilicity with the aim of improving metabolic stability (Table 6 ).
Replacement of the pyrrolidine by an azetidine (compound 20) did not lead to improved metabolic stability in all species; however, the racemic piperazine and morpholine derivatives (21 and 22, respectively) resulted in improved CL int profiles across all species. Disappointingly, we observed a decrease in the biochemical CDK8 affinity and the cellular potency (Table  6 ).
In summary, the microsomal stability could be improved by reducing overall lipophilicity; however, a corresponding drop in biochemical and cell-based activity was also observed. Therefore, we attempted to improve the metabolic stability by reducing the lipophilicity of the molecule through the introduction of polarity into the hinge-binding scaffold.
4. Fine-Tuning of the Hinge Binding Motif. The pyrazole hinge binding motif was fixed and the six-membered ring of the indazole scaffold was varied by introduction of single nitrogen atoms in the 4-, 6-, and 7-positions to reduce the overall lipophilicity of the scaffold (compounds 23−25, Table 7 ). Introduction of a nitrogen atom at the 6-position of the indazole ring (23) resulted in a significant drop in biochemical and cell-based potency. Nitrogen at the 4-position of the indazole ring gave the most potent analogue (24); however, this compound showed only modest microsomal stability. Pleasingly, introduction of a nitrogen atom at the 7-position (25) resulted in acceptable biochemical CDK8 affinity and furthermore showed improved microsomal stability ( Table 7) .
The matched molecular pair compound 25 versus compound 6, where only the hinge binding scaffold ("pyrazolo-pyridine" vs "imidazo-thiadiazole") has been changed, showed equivalent biochemical CDK8 affinity and a 11-fold improvement in cellbased potency together with a significant improvement in mouse and rat microsomal stability.
We next determined the crystal structure of 25 bound to CDK8/cyclin C ( Figure 5A ). The carbonyl atom at C5 of the azaindazole scaffold of 25 forms a hydrogen bond to Lys52 and the side chain of Lys52 moves toward the ligand in comparison to the binding mode of compound 6 in CDK8/cyclin C ( Figure   5B ). Overall, the orientation of the active site residues is well conserved between the crystal structures of 25 and 6. The interaction pattern is identical except for an additional favorable interaction from the N1-indazole hydrogen bond donor to the backbone CO atom of Asp98 for 25. Notably, the additional nitrogen atom at the 7-position of the indazole scaffold does not elicit any additional favorable interactions consistent with the corresponding biochemical potencies: indazole 10 (CDK8 IC 50 = 1.4 nM) versus aza-indazole 25 (CDK8 IC 50 = 2.6 nM).
In a commercially available reporter displacement assay, 46 compound 25 binds to CDK8 and CDK19 with similar affinity (4 nM), as we have previously observed across multiple chemotypes, 27 the compound showed acceptable pharmacokinetics (PK) in all tested preclinical species (Table 8) . Prediction of the human PK was performed by three species allometric scaling corrected for protein binding and considering interspecies differences in intrinsic clearance in liver microsomes. The human clearance (CL) and volume of distribution at steady-state (Vd ss ) were estimated to be low (∼0.14 L/h/kg) and small (0.48 L/kg), respectively, resulting in a short predicted terminal half-life (2.4 h). Physiologically based pharmacokinetics (PBPK) simulations suggested that human oral bioavailability may be ≥75% up to dose level of 500 mg daily.
Compound 25 was then assessed in vivo in an established SW620 human colorectal cancer xenograft model in female NCr athymic mice. Tumor-bearing mice were treated orally with compound 25 (50 mg/kg bid or 100 mg/kg qd) for 16 days. Both schedules gave a similar reduction in tumor growth ( Figure 6A ) with T/C ratios (based on final tumor weights) of 49% and 57%, respectively. The compound was generally well tolerated, with no effects on mouse body weight in the qd administration schedule and manageable body weight loss with the bid schedule ( Figure 6B ). We monitored inhibition of STAT1 SER727 phosphorylation by a Luminex immunoassay; phospho-STAT1 SER727 levels were reduced to the limits of detection 2 h after dosing in both administration schedules and remained below the control levels even after 24 h, having more pronounced effects in the bid compared with the qd schedule ( Figure 6C ).
■ CONCLUSIONS
In an HTS campaign using a FRET-based Lanthascreen binding competition assay, we identified a chemical series comprising an imidazo-thiadiazole scaffold with exemplar compounds demonstrating IC 50 values in the 60−780 nM range (Table 1) ; however, this series lacked sufficient microsomal stability. Determination of the crystal structure of compound 6 in CDK8/cyclin C demonstrated clear differences in binding mode compared to our previously reported 3,4,5 trisubstituted-2-aminopyridine series. 27 SZMAP and WaterMap calculations were applied to identify potential scaffold replacements to enhance potency and improve metabolic stability. By applying these computational approaches, we explored changes to the skeleton of the five-membered ring of the imidazothiadiazole hinge binding motif and discovered a series of indazole-based scaffold replacements. Notably, 3-methyl indazole 10 demonstrated potent biochemical and cell-based potency; however, insufficient metabolic stability precluded further progression. Replacement of the C3-methyl substituent with a C3-amino group gave compound 13, which demon- strated optimal biochemical potency and metabolic stability but suffered from undesirable off-target kinase affinity.
We employed selectivity grids to rationalize key regions for the modulation of kinase selectivity for the most notable offtarget kinases, and discovered that selectivity could be improved by modifications to the pyrrolidine ring and by variation of the para-halogen substituent on the pendant phenyl ring to give, for example, the selective and metabolically stable para-fluorophenylpiperidine analogue 17. Crystallization of 17 in CDK8/cyclin C revealed a conserved binding mode; however, 17 lacked the desired biochemical potency and cellular activity.
Revisiting the C3-methylindazole series and applying the principle of reduced lipophilicity to abrogate oxidative metabolism enabled the synthesis of potent and selective analogues with improved cell-based potency compared to 3-amino-indazole 17. In particular, the 7-azaindole scaffold exemplified by compound 25, which demonstrated an optimal compromise of biochemical and cell-based potency coupled with acceptable in vitro metabolic stability that resulted in a favorable in vivo oral pharmacokinetic profile in mouse, rat, and dog. Compound 25 demonstrated reduction of tumor growth rates of established human SW620 colorectal carcinoma xenografts using two different oral dosing schedules. We observed concomitant inhibition of a target engagement biomarker phospho-STAT1 SER727 consistent with pharmacokinetic exposure.
In light of its potent and selective profile coupled with good oral pharmacokinetics and duration of in vivo target engagement on oral dosing, compound 25 (MSC2530818) was selected for progression into further preclinical in vivo animal efficacy and safety studies.
■ EXPERIMENTAL SECTION
Chemistry. Commercially available starting materials, reagents, and dry solvents were used as supplied. Column chromatography was performed on a CombiFlash Companion purification system using Teledyne Isco silica cartridges. Preparative TLC was performed on Merck plates. Preparative HPLC was conducted according the following methods. Method A: injections of the sample were made onto a SunFire C18 OBD column (100 Å, 5 μm, 30 mm × 100 mm). Chromatographic separation at room temperature was carried out using Agilent Technologies, 1260 Infinity, acetonitrile:water gradient (both modified with 0.1% trifluoroacetic acid) at a flow rate of 50 mL/ min. Chiral preparative HPLC was conducted according the following methods. Method B: Injections of the sample were made onto a ChiralPak AD-H column (5 μm, 4.6 mm × 250 mm). Chiral chromatographic separation was carried at room temperature out using SFC Berger Minigram, CO 2 /methanol (85:15) + 0.5% diethyl amine at a flow rate of 5 mL/min. Method C: Injections of the sample were made onto a ChiralPak AS-H column (5 μm, 4.6 mm × 250 mm). Chiral chromatographic separation was carried at room temperature out using SFC Berger Minigram, CO 2 /methanol (60:40), modified with 0.5% diethyl amine, at a flow rate of 5 mL/min. Method D: Injections of the sample were made onto a ChiralPak AD-H column (5 μm, 4.6 mm × 250 mm). Chiral chromatographic separation was carried at room temperature out using SFC Berger Minigram, CO 2 / methanol (75:25) + 0.5% diethyl amine, at a flow rate of 5 mL/min. Additional methods are directly described in the procedures. 1 H NMR spectra were recorded on a Bruker Avance-500, Avance 400, Avance II 400, or Avance 300. Samples were prepared as solutions in a deuterated solvent and referenced to the appropriate internal nondeuterated solvent peak. 13 C NMR spectra were recorded at 101 MHz using an internal deuterium lock. The following internal references were used: CDCl 3 , CD 3 OD, and DMSO-d 6 . LC/MS and HRMS analysis was performed on an Agilent 1200 series HPLC and diode array detector coupled to a 6210 time-of-flight mass spectrometer with dual multimode APCI/ESI source. Analytical separation was carried out according to the following method. Method E: Analytical separation was carried out on a Chromolith Speed ROD column (RP-18e, 50 mm × 4.6 mm) using a flow rate of 2.4 mL/min in a 3.9 min gradient elution with detection at 220 nm. The mobile phase was a mixture of water containing 0.05% formic acid (solvent A) and acetonitrile containing 0.04% formic acid (solvent B + 609.280657. All compounds submitted for biological testing were determined to be >95% pure by methods E, F, or G unless stated otherwise.
The synthesis of the two key compounds 13 and 25 will be described in the following. The synthesis of the remaining compounds can be found in the Supporting Information. All other experimental details (mouse, rat, and human Cl int determination; Caco-2 determination; in vivo mouse PK in-life phase; in vivo rat and dog PK in-life phase; bioanalytics; prediction of human clearance; in vitro cell-based reporter assays, 7dF3 luciferase reporter assay; in vitro biochemical assays, CDK8 Lanthascreen binding assay and reporter displacement assay for CDK19; human tumor xenograft efficacy study; pharmacokinetic analysis; tumor xenograft processing; and Luminex analysis) are described in previous publications. 27, 30 All animal experiments were conducted in accordance with local and United Kingdom National Cancer Research Institute guidelines. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.6b00597.
Synthesis protocols and analytical data; crystallographic data of compounds 6, 17, and 25; kinase selectivity data for compounds 13 and 25; activity of compound 25 tested at 10 μM across a panel of 59 receptors and ion channels (CEREP) and Omit maps (PDF)
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